A Randomized, Double Blind, Placebo Controlled, Single Ascending Dose Study With Lurasidone Injectable Suspension to Evaluate Safety, Tolerability and Pharmacokinetics in Subjects With Schizophrenia
Phase of Trial: Phase I
Latest Information Update: 05 Apr 2019
Price : $35 *
At a glance
- Drugs Lurasidone (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Sunovion Pharmaceuticals
- 01 Apr 2019 Status changed from recruiting to completed.
- 04 Mar 2019 Planned End Date changed from 15 Oct 2019 to 29 Mar 2019.
- 04 Mar 2019 Planned primary completion date changed from 15 Oct 2019 to 29 Mar 2019.